论文部分内容阅读
目的观察生脉注射液加大剂量维生素C防治尿激酶溶栓治疗急性心肌梗塞(AMI)再灌注损伤的疗效及其安全性。方法将符合溶栓标准的AMI患者60例随机分为治疗组和对照组;对照组予尿激酶溶栓治疗,治疗组在此基础上加用生脉注射液及大剂量维生素C;观察胸痛程度及持续时间、心电图、心肌酶、并发症及4周病死率。结果治疗组再灌注心律失常发生率、心力衰竭发生率及4周内病死率均显著低于对照组(P<0.05),两组治疗过程中均未发生严重出血并发症。结论生脉注射液及大剂量维生素C可防治尿激酶溶栓治疗AMI再灌注损伤并具有较满意的安全性。
Objective To observe the curative effect and safety of Shengmai injection plus large dosage of vitamin C on prevention and treatment of acute myocardial infarction (AMI) reperfusion injury by urokinase thrombolysis. Methods Thirty patients with acute myocardial infarction (AMI) who met thrombolysis criteria were randomly divided into treatment group and control group. The control group received urokinase thrombolytic therapy. On the basis of this, Shengmai injection and high-dose vitamin C were added to the treatment group. And duration, ECG, myocardial enzymes, complications and 4-week mortality. Results The incidence of reperfusion arrhythmia, the incidence of heart failure and the mortality within 4 weeks in the treatment group were significantly lower than those in the control group (P <0.05). No severe bleeding complications occurred in the two groups. Conclusion Shengmai injection and high-dose vitamin C can prevent urokinase thrombolysis in AMI reperfusion injury with satisfactory safety.